Sonic Healthcare Limited (ASX:SHL)

Market Cap	10.09B -21.6%
Revenue (ttm)	10.42B +11.7%
Net Income	539.40M -1.1%
EPS	1.11 -2.7%
Shares Out	494.08M
PE Ratio	18.47
Forward PE	16.08
Dividend	1.07 (5.20%)
Ex-Dividend Date	Mar 4, 2026

Volume	1,451,932
Open	20.42
Previous Close	20.58
Day's Range	20.36 - 20.78
52-Week Range	18.26 - 29.24
Beta	0.58
Analysts	Hold
Price Target	24.25 (+18.76%)
Earnings Date	Aug 18, 2026

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1934
• Employees: 45,000
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SHL

Financial Performance

In fiscal year 2025, Sonic Healthcare's revenue was 9.65 billion, an increase of 7.56% compared to the previous year's 8.97 billion. Earnings were 513.60 million, an increase of 0.49%.

Analyst Summary

According to 16 analysts, the average rating for SHL stock is "Hold." The 12-month stock price target is $24.25, which is an increase of 18.76% from the latest price.

Price Target

$24.25

(18.76% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error